Takeda Pharmaceutical Company Limited
Inhibitors of plasma kallikrein and uses thereof
Last updated:
Abstract:
The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
Status:
Grant
Type:
Utility
Filling date:
22 Jun 2020
Issue date:
7 Jun 2022